Table 2.
Comparisons of the Clinical Data Between Those With and Without Atypical Psychosis Within a Year Since CSCI Treatment
| No atypical psychosis | Atypical psychosis | p Value | Adjusted p | |||
| N | Mean ± SEM | N | Mean ± SEM | |||
| Age (y) | 17 | 66.65 ± 1.85 | 6 | 67.17 ± 4.44 | 0.899 | 1 |
| Age at onset (y) | 17 | 53.29 ± 1.76 | 6 | 53.00 ± 4.49 | 0.471 | 1 |
| Sex (male: female) | 17 | 8: 9 | 6 | 3: 3 | 0.901 | 1 |
| Disease duration (y) | 17 | 13.35 ± 1.19 | 6 | 14.17 ± 2.52 | 0.746 | 1 |
| HY score, disease severity | 17 | 2.94 ± 0.18 | 6 | 2.83 ± 0.17 | 0.742 | 1 |
| MDS-UPDRS Part III score | 17 | 22.71 ± 2.01 | 6 | 22.00 ± 3.45 | 0.86 | 1 |
| PDQ39 score | 14 | 54.29 ± 4.57 | 6 | 65.83 ± 9.17 | 0.222 | 1 |
| LED before CSCI (mg) | 17 | 682.94 ± 54.20 | 6 | 779.67 ± 76.94 | 0.355 | 1 |
| CSCI initial dose (mL/h) | 17 | 0.25 ± 0.015 | 6 | 0.28 ± 0.03 | 0.325 | 1 |
| Maximum CSCI dose within 1 y (mL/h) | 17 | 0.32 ± 0.02 | 6 | 0.38 ± 0.04 | 0.165 | 1 |
| Agonist use (yes: no) | 17 | 15: 2 | 6 | 6: 0 | 0.379 | 1 |
| MMSE score | 16 | 28.63 ± 0.015 | 6 | 27.17 ± 1.30 | 0.185 | 1 |
| FAB score | 14 | 16.29 ± 0.56 | 6 | 14.33 ± 1.23 | 0.11 | 1 |
| RBDQ score | 13 | 4.85 ± 0.67 | 6 | 3.50 ± 1.18 | 0.301 | 1 |
| QUIP-CS score | 14 | 0.64 ± 0.22 | 6 | 3.50 ± 0.81 | 0.00021 | 0.0032 |
Abbreviations: CSCI = continuous subcutaneous infusion; HY = Hoehn and Yahr scale; MDS-UPDRS = Movement Disorder Society–Unified Parkinson's Disease Rating Scale; PDQ39 = Parkinson's Disease Questionnaire; LED = levodopa equivalent dose; MMSE = Mini-Mental State Examination; FAB = Frontal Assessment Battery; RBDQ = Rapid Eye Movement Sleep Behavior Disorder Questionnaire; QUIP-CS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease–Current Symptoms.
Chi-squared tests were used for categorical variables (sex and agonist use) while Student t tests were applied to continuous variables.